Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Operating Leases (2019 - 2026)

Myriad Genetics has reported Operating Leases over the past 7 years, most recently at $89.9 million for Q4 2025.

  • Quarterly Operating Leases rose 2.28% to $89.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.9 million through Dec 2025, up 2.28% year-over-year, with the annual reading at $89.9 million for FY2025, 2.28% up from the prior year.
  • Operating Leases was $89.9 million for Q4 2025 at Myriad Genetics, up from $84.9 million in the prior quarter.
  • Over five years, Operating Leases peaked at $130.9 million in Q4 2022 and troughed at $5.9 million in Q1 2023.
  • The 5-year median for Operating Leases is $86.8 million (2022), against an average of $76.9 million.
  • Year-over-year, Operating Leases crashed 95.21% in 2023 and then skyrocketed 1498.31% in 2024.
  • A 5-year view of Operating Leases shows it stood at $79.3 million in 2021, then surged by 65.07% to $130.9 million in 2022, then decreased by 25.59% to $97.4 million in 2023, then fell by 9.75% to $87.9 million in 2024, then grew by 2.28% to $89.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Operating Leases are $89.9 million (Q4 2025), $84.9 million (Q3 2025), and $86.2 million (Q2 2025).